Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations.

Miklja Z, Pasternak A, Stallard S, Nicolaides T, Kline-Nunnally C, Cole B, Beroukhim R, Bandopadhayay P, Chi S, Ramkissoon SH, Mullan B, Bruzek AK, Gauthier A, Garcia T, Atchison C, Marini B, Fouladi M, Parsons DW, Leary S, Mueller S, Ligon KL, Koschmann C.

Neuro Oncol. 2019 Feb 26. pii: noz022. doi: 10.1093/neuonc/noz022. [Epub ahead of print]

PMID:
30805642
2.

Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.

Johnson A, Severson E, Gay L, Vergilio JA, Elvin J, Suh J, Daniel S, Covert M, Frampton GM, Hsu S, Lesser GJ, Stogner-Underwood K, Mott RT, Rush SZ, Stanke JJ, Dahiya S, Sun J, Reddy P, Chalmers ZR, Erlich R, Chudnovsky Y, Fabrizio D, Schrock AB, Ali S, Miller V, Stephens PJ, Ross J, Crawford JR, Ramkissoon SH.

Oncologist. 2017 Dec;22(12):1478-1490. doi: 10.1634/theoncologist.2017-0242. Epub 2017 Sep 14.

3.

Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.

Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, Aboian M, Cha S, Raleigh DR, Braunstein S, Torkildson J, Samuel D, Bloomer M, Campomanes AGA, Banerjee A, Butowski N, Raffel C, Tihan T, Bollen AW, Phillips JJ, Korn WM, Yeh I, Bastian BC, Gupta N, Mueller S, Perry A, Nicolaides T, Solomon DA.

Neuro Oncol. 2017 May 1;19(5):699-709. doi: 10.1093/neuonc/now254.

4.

Pediatric low-grade gliomas: next biologically driven steps.

Jones DTW, Kieran MW, Bouffet E, Alexandrescu S, Bandopadhayay P, Bornhorst M, Ellison D, Fangusaro J, Fisher MJ, Foreman N, Fouladi M, Hargrave D, Hawkins C, Jabado N, Massimino M, Mueller S, Perilongo G, Schouten van Meeteren AYN, Tabori U, Warren K, Waanders AJ, Walker D, Weiss W, Witt O, Wright K, Zhu Y, Bowers DC, Pfister SM, Packer RJ.

Neuro Oncol. 2018 Jan 22;20(2):160-173. doi: 10.1093/neuonc/nox141. Review.

5.

Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology.

Linzey JR, Marini BL, Pasternak A, Smith C, Miklja Z, Zhao L, Kumar-Sinha C, Paul A, Harris N, Robertson PL, Hoffman LM, Chinnaiyan A, Mody R, Koschmann C.

J Neurooncol. 2018 Mar;137(1):155-169. doi: 10.1007/s11060-017-2708-1. Epub 2017 Dec 12.

6.

Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors.

Pincez T, Clément N, Lapouble E, Pierron G, Kamal M, Bieche I, Bernard V, Fréneaux P, Michon J, Orbach D, Aerts I, Pacquement H, Bourdeaut F, Jiménez I, Thébaud E, Oudot C, Vérité C, Taque S, Owens C, Doz F, Le Tourneau C, Delattre O, Schleiermacher G.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26365. Epub 2016 Nov 29.

PMID:
27896933
7.

Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas.

Ramkissoon LA, Britt N, Guevara A, Whitt E, Severson E, Sathyan P, Gay L, Elvin J, Ross JS, Brown C, Stogner-Underwood K, Mott R, Kram D, Strowd R, Lesser GJ, Ramkissoon SH.

Curr Treat Options Oncol. 2018 Jun 21;19(8):41. doi: 10.1007/s11864-018-0559-4. Review.

PMID:
29931654
8.

Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas.

Juratli TA, Qin N, Cahill DP, Filbin MG.

Pharmacol Ther. 2018 Feb;182:70-79. doi: 10.1016/j.pharmthera.2017.08.006. Epub 2017 Aug 19. Review.

PMID:
28830841
9.

Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.

Movassaghi M, Shabihkhani M, Hojat SA, Williams RR, Chung LK, Im K, Lucey GM, Wei B, Mareninov S, Wang MW, Ng DW, Tashjian RS, Magaki S, Perez-Rosendahl M, Yang I, Khanlou N, Vinters HV, Liau LM, Nghiemphu PL, Lai A, Cloughesy TF, Yong WH.

Exp Mol Pathol. 2017 Aug;103(1):87-93. doi: 10.1016/j.yexmp.2017.06.006. Epub 2017 Jun 27.

PMID:
28663030
10.

Advances in the molecular genetics of gliomas - implications for classification and therapy.

Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M.

Nat Rev Clin Oncol. 2017 Jul;14(7):434-452. doi: 10.1038/nrclinonc.2016.204. Epub 2016 Dec 29. Review.

11.

Low Grade Gliomas in Children.

Chalil A, Ramaswamy V.

J Child Neurol. 2016 Mar;31(4):517-22. doi: 10.1177/0883073815599259. Epub 2015 Aug 18. Review.

PMID:
26286938
12.

Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas.

Garcia MA, Solomon DA, Haas-Kogan DA.

Future Oncol. 2016 Jun;12(12):1493-506. doi: 10.2217/fon-2016-0039. Epub 2016 Apr 13. Review.

13.

Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.

Oberg JA, Glade Bender JL, Sulis ML, Pendrick D, Sireci AN, Hsiao SJ, Turk AT, Dela Cruz FS, Hibshoosh H, Remotti H, Zylber RJ, Pang J, Diolaiti D, Koval C, Andrews SJ, Garvin JH, Yamashiro DJ, Chung WK, Emerson SG, Nagy PL, Mansukhani MM, Kung AL.

Genome Med. 2016 Dec 23;8(1):133. doi: 10.1186/s13073-016-0389-6.

14.

The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.

Dasgupta T, Haas-Kogan DA.

Front Oncol. 2013 May 10;3:110. doi: 10.3389/fonc.2013.00110. eCollection 2013.

15.

Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management.

Sturm D, Pfister SM, Jones DTW.

J Clin Oncol. 2017 Jul 20;35(21):2370-2377. doi: 10.1200/JCO.2017.73.0242. Epub 2017 Jun 22. Review.

PMID:
28640698
16.

Input of molecular analysis in medical management of primary brain tumor patients.

Idbaih A, Duran-Peña A, Bonnet C, Ducray F.

Rev Neurol (Paris). 2015 Jun-Jul;171(6-7):457-65. doi: 10.1016/j.neurol.2015.04.002. Epub 2015 May 27. Review.

PMID:
26026669
17.

Translating genomic discoveries to the clinic in pediatric oncology.

Glade Bender J, Verma A, Schiffman JD.

Curr Opin Pediatr. 2015 Feb;27(1):34-43. doi: 10.1097/MOP.0000000000000172. Review.

PMID:
25502895
18.

Precision medicine in pediatric oncology: Lessons learned and next steps.

Mody RJ, Prensner JR, Everett J, Parsons DW, Chinnaiyan AM.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26288. Epub 2016 Oct 17. Review.

19.

Pediatric low-grade gliomas: implications of the biologic era.

Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhayay P, Bornhorst M, Bowers DC, Ellison D, Fangusaro J, Foreman N, Fouladi M, Gajjar A, Haas-Kogan D, Hawkins C, Ho CY, Hwang E, Jabado N, Kilburn LB, Lassaletta A, Ligon KL, Massimino M, Meeteren SV, Mueller S, Nicolaides T, Perilongo G, Tabori U, Vezina G, Warren K, Witt O, Zhu Y, Jones DT, Kieran M.

Neuro Oncol. 2017 Jun 1;19(6):750-761. doi: 10.1093/neuonc/now209. Review.

20.

A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method.

Walker DA, Liu J, Kieran M, Jabado N, Picton S, Packer R, St Rose C; CPN Paris 2011 Conference Consensus Group.

Neuro Oncol. 2013 Apr;15(4):462-8. doi: 10.1093/neuonc/nos330. Epub 2013 Mar 15. Review.

Supplemental Content

Support Center